The Oncotype DX® Colon Recurrence Score™ assay
The Oncotype DX® Colon Recurrence Score™ assay is clinically validated to quantify the risk of recurrence of patients with anatomic stage II, MMR-P and stage III A/B colon cancers.1-4 The 12-gene genomic test (seven cancer-related genes and five reference genes) looks at the underlying biology of a patient’s tumor—to help you choose a treatment that fits their unique situation.
The only genomic test for colon cancer with Level 1 evidence1-4, the Oncotype DX® Colon Recurrence Score™ assay gives you information that clinical and pathologic factors alone cannot provide. Four validation studies—QUASAR, CALGB 9581, NSABP C-07, and SUNRISE—confirm that the Recurrence Score result predicts the risk of local recurrence.1-4
Performed on a tumor sample collected during your patient’s resection, the test looks at the activity of 12 genes in the tumor. The results are quantitative, reproducible, and offer an individualized assessment of risk for patients with either anatomic stage II, MMR-P or stage III A/B colon cancers.1-4
The Recurrence Score results provide an estimate of the risk of recurrence for anatomic stage II, MMR-P and stage III A/B patients to help guide the most appropriate treatment decision. 1-4
The Colon Recurrence Score® report includes the “Recurrence Score result”, which is a number between 0-100. A low score means a lower chance of recurrence and a high score means a higher chance of recurrence.1-4
For further information, please go to oncotypeiq.com/en
REFERENCES
1. Gray et al. J Clin Oncol. 2011.
2. Venook et al. J Clin Oncol. 2013.
3. Yothers et al. J Clin Oncol. 2013.
4. Yamanaka et al. J Clin Oncol. 2016.
The only genomic test for colon cancer with Level 1 evidence1-4, the Oncotype DX® Colon Recurrence Score™ assay gives you information that clinical and pathologic factors alone cannot provide. Four validation studies—QUASAR, CALGB 9581, NSABP C-07, and SUNRISE—confirm that the Recurrence Score result predicts the risk of local recurrence.1-4
Performed on a tumor sample collected during your patient’s resection, the test looks at the activity of 12 genes in the tumor. The results are quantitative, reproducible, and offer an individualized assessment of risk for patients with either anatomic stage II, MMR-P or stage III A/B colon cancers.1-4
The Recurrence Score results provide an estimate of the risk of recurrence for anatomic stage II, MMR-P and stage III A/B patients to help guide the most appropriate treatment decision. 1-4
The Colon Recurrence Score® report includes the “Recurrence Score result”, which is a number between 0-100. A low score means a lower chance of recurrence and a high score means a higher chance of recurrence.1-4
For further information, please go to oncotypeiq.com/en
REFERENCES
1. Gray et al. J Clin Oncol. 2011.
2. Venook et al. J Clin Oncol. 2013.
3. Yothers et al. J Clin Oncol. 2013.
4. Yamanaka et al. J Clin Oncol. 2016.
Oncotype DX, Oncotype DX Breast Recurrence Score, Oncotype DX Genomic Prostate Score, GPS, Recurrence Score, Colon Recurrence Score, and Genomic Prostate Score are trademarks or registered trademarks of Genomic Health, Inc. Used under license.